# Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19

> **NCT04354259** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 157 (actual)

## Conditions studied

- Sars-CoV2
- Covid-19

## Interventions

- **DRUG:** Peginterferon Lambda-1A
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04354259
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-13
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-12-08
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2023-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04354259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04354259, "Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04354259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*